Journal article
Effect of Alirocumab on Mortality After Acute Coronary Syndromes
Abstract
BACKGROUND: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome.
METHODS: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab …
Authors
Steg PG; Szarek M; Bhatt DL; Bittner VA; Brégeault M-F; Dalby AJ; Diaz R; Edelberg JM; Goodman SG; Hanotin C
Journal
Circulation, Vol. 140, No. 2, pp. 103–112
Publisher
Wolters Kluwer
Publication Date
July 9, 2019
DOI
10.1161/circulationaha.118.038840
ISSN
0009-7322